CROHN'S DISEASE IN A YOUNG ADULT WITH AN ATYPICAL INITIAL PRESENTATION: A CASE REPORT
DOI:
https://doi.org/10.56238/revgeov17n3-016Keywords:
Crohn's Disease, Inflammatory Bowel Disease, NSAID-Induced Colitis, Chronic Diarrhea, Case ReportAbstract
A.F.A., a 23-year-old male, previously healthy, was admitted due to pain and weakness in his lower limbs, a condition that began 90 days prior. Electroneuromyography revealed bilateral lumbar radiculopathy. During the clinical course, he presented with unintentional weight loss, abdominal pain, and chronic diarrhea. Further investigation revealed elevated fecal calprotectin, and colonoscopy demonstrated continuous inflammation with extensive ulcerations from the sigmoid colon to the cecum, with histopathology showing marked acute and chronic colitis. This case illustrates the diagnostic complexity of inflammatory bowel disease, especially in the face of atypical initial presentations with predominantly extraintestinal manifestations and the concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), factors that can delay clinical suspicion and adequate gastrointestinal investigation.
Downloads
References
1. Baumgart DC, Cheng CH, Du TX, et al.Network analysis of extraintestinal manifestations and associated autoimmune disorders in Crohn’s disease and ulcerative colitis. NPJ Digit Med. 2025;8:209. doi:10.1038/s41746-025-01504-6
2. Caballero-Mateos AM, Brunet-Mas E, Gros B.Systemic consequences of inflammatory bowel disease beyond immune-mediated manifestations. J Clin Med. 2025;14(22):7984. doi:10.3390/jcm14227984
3. Caruso A, Latella G, Di Giacomo D, Cavicchioli M, Galli F.Inflammatory bowel diseases (IBDs): a cross-sectional analysis of the psychological and biological mechanisms underlying intestinal and extra-intestinal symptoms – GastroPsy study protocol. BMJ Open. 2025;15(11):e103374. doi:10.1136/bmjopen-2025-103374
4. Gao X, Cao Q, Cheng Y, et al. Chronic stress promotes colitis by disturbing the gut–brain axis. Cell Mol Gastroenterol Hepatol. 2022;13(2):421–443. doi:10.1016/j.jcmgh.2021.09.005
5. Katsanos AH, Katsanos KH. Neurological manifestations of inflammatory bowel disease. Ann Gastroenterol. 2020;33(1):5–15.
6. Kobayashi T, Siegmund B, Le Berre C, et al.Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. doi:10.1038/s41572-020-0205-x
7. Lossos A, River Y, Eliakim A, Steiner I. Neurologic manifestations of inflammatory bowel disease. J Neurol. 2021;268(10):3726–3734. doi:10.1007/s00415-020-10360-2
8. Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review: nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Aliment Pharmacol Ther. 2021;53(7):737–745. doi:10.1111/apt.16275
9. Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for diagnosis of inflammatory bowel disease activity. Am J Gastroenterol. 2021;116(3):513–523. doi:10.14309/ajg.0000000000001116
10. Parra RS, Rocha JJR, Féres O. Manifestações extraintestinais na doença inflamatória intestinal. Arq Gastroenterol. 2020;57(3):286–292. doi:10.1590/S0004-2803.202000000-55
11. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi:10.1093/ecco-jcc/jjab178
12. Sociedade Brasileira de Coloproctologia.Diretrizes brasileiras para o manejo da retocolite ulcerativa. Rev Col Bras Cir. 2021.
13. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2023;401(10386):1280–1295. doi:10.1016/S0140-6736(22)02511-9
14. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(9):1323–1335. doi:10.1093/ibd/izz322
